Physics and biomedical challenges of cancer therapy with accelerated heavy ions

Radiotherapy should have low toxicity in the entrance channel (normal tissue) and be very effective in cell killing in the target region (tumour). In this regard, ions heavier than protons have both physical and radiobiological advantages over conventional X-rays. Carbon ions represent an excellent combination of physical and biological advantages. There are a dozen carbon-ion clinical centres in Europe and Asia, and more under construction or at the planning stage, including the first in the USA. Clinical results from Japan and Germany are promising, but a heated debate on the cost-effectiveness is ongoing in the clinical community, owing to the larger footprint and greater expense of heavy ion facilities compared with proton therapy centres. We review here the physical basis and the clinical data with carbon ions and the use of different ions, such as helium and oxygen. Research towards smaller and cheaper machines with more effective beam delivery is necessary to make particle therapy affordable. The potential of heavy ions has not been fully exploited in clinics and, rather than there being a single 'silver bullet', different particles and their combination can provide a breakthrough in radiotherapy treatments in specific cases. Radiotherapy with accelerated heavy ions is a potential breakthrough in cancer therapy. This Review discusses the challenges in physics and radiobiology to make this therapy affordable and to fully exploit the clinical benefits.

Automated summary

Carbon ions represent a promising combination of physical and biological advantages for radiotherapy, with clinical results showing potential breakthroughs. However, the cost-effectiveness and comparison to proton therapy centers continue to be a topic of debate in the clinical community. Research towards smaller, cheaper machines with more effective beam delivery is seen as necessary to make particle therapy more affordable and fully exploit the clinical benefits.